The Serotonergic System: Its Role in Pathogenesis and Early Developmental Treatment of Autism

Authors: Zafeiriou, D. I.; Ververi, A.; Vargiami, E.

Source: Current Neuropharmacology, Volume 7, Number 2, June 2009 , pp. 150-157(8)

Publisher: Bentham Science Publishers

Buy & download fulltext article:

Price: $63.10 plus tax (Refund Policy)

Abstract:

Autism is a severe childhood disorder already presenting in the first 3 years of life and, therefore, strongly correlated with neurodevelopmental alterations in prenatal, as well as postnatal period. Neurotransmitters hold a pivotal role in development by providing the stimulation needed for synapses and neuronal networks to be formed during the critical period of neuroplasticity. Aberrations of the serotonergic system modify key processes in the developing brain and are strongly implicated in the pathophysiology of developmental disorders. Evidence for the role of serotonin in autism emerges from neuropathological, imaging and genetic studies. Due to its developmental arrest, autism requires early intervention that would, among others, target the disrupted serotonergic system and utilize brain plasticity to elicit clinically important brain changes in children.

Keywords: Autism; serotonin; serotonergic; developmental intervention; plasticity; 5-hydroxytryptophan

Document Type: Research article

DOI: http://dx.doi.org/10.2174/157015909788848848

Publication date: 2009-06-01

More about this publication?

Current Neuropharmacology aims to provide current, timely and comprehensive reviews of all areas of neuropharmacology and related matters of neuroscience. The journal publishes reviews written by experts and leaders in the fields of molecular, cellular, and systems/behavioural aspects of neuropharmacology and neuroscience. The journal serves as a comprehensive, multidisciplinary expert forum for neuropharmacologists and neuroscientists.